Animal Biologics & Vaccines
Manufacturers of veterinary vaccines and biologic products.
Market snapshot
These figures describe Animal Health Pharmaceuticals (4.11.2), the segment that Animal Biologics & Vaccines sits within — not Animal Biologics & Vaccines on its own.
Within pharmaceutical manufacturing (NAICS 325412/325414); the Census Bureau does not separate animal-health pharmaceuticals, so the segment is not separately sized here.
Business model & economics
Revenue model
Vaccine, parasiticide, and therapeutic product sales
Key economics
- Recurring revenue
- High
- EBITDA margin
- Strong
- Capex intensity
- High
recurring vaccines, parasiticides, and chronic meds
branded animal-pharma economics
Characteristics
- Companion-animal pharma the growth engine.
- Novel therapies (mAbs, derm, parasiticides) drive growth.
- Production-animal pharma mature and antibiotic-pressured.
Geographic concentration
Animal-health pharmaceutical makers cluster in New Jersey and Massachusetts (human-pharma spillover), with specialized hubs in Utah and Colorado.
U.S. Census Bureau — 2022 County Business Patterns (establishments by state), NAICS 325412/325414. Concentration shown by location quotient.
M&A deal context
Who’s acquiring
- Animal-health pharma strategics
- Pharma & diversified acquirers
- PE- and VC-backed innovators
What’s driving deals
- Companion-animal novel-therapy innovation.
- Consolidation around global strategics.
- Acquisition of pet-pharma and biologic innovation.
Find Animal Biologics & Vaccines acquisition targets
Search Acquisera’s index for companies classified under Animal Biologics & Vaccines (4.11.2.1) and build a targeted deal pipeline.
Search companies